
Preclinical evaluation of zoledronate using an in vitro mimetic cellular model for breast cancer metastatic bone disease
Keywords: BPs; bisphosphonates; ZOL; zoledronate; RANKL; receptor activator of nuclear factor-κB ligand; NTx; N-terminal telopeptide; CATK; cathepsin K; OPG; osteoprotegerin; PTHrP; parathyroid hormone-related peptide; M-CSF; macrophage colony-stimulating factor;